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Abstract The prevalence and regulation of p38 mitogen
activated protein kinase (MAPK) expression in human
lymphomas have not been extensively studied. In order to
elucidate the role of p38 MAPK in lymphomagenesis, we
examined the expression of native and phosphorylated p38
(p-p38) MAPK in cell lines derived from human hemato-
poietic neoplasms including B cell lymphoma-derived cell
lines using Western blot analysis. The p-p38 MAPK protein
was also analyzed in 30 B cell non-Hodgkin lymphoma
(NHL) tissue biopsies by immunohistochemistry. Our
results show that the expression of p38 MAPK was up-
regulated in most of the cell lines as compared with
peripheral blood lymphocytes, while the expression of
p-p38 MAPK was more variable. A subset of B cell NHL
biopsies showed increased expression of p-p38 MAPK
relative to reactive germinal center cells. Interleukin-4
(IL-4) induced a dose-dependent increase in the expression
of p-p38 MAPK (1.6- to 2.8-fold) in cell lines derived from
activated B cell-like diffuse large B cell lymphoma
(DLBCL) but not those from germinal center-like DLBCL.
No change was seen in native p38 MAPK. The in vitro
kinase activity of p38 MAPK, however, was induced (1.6-
to 3.2-fold) in all five cell lines by IL-4. Quantitative
fluorescent RT-PCR demonstrated that all four isoforms of
p38 MAPK gene were expressed in the lymphoma cell
lines, with p38γ and p38β isoforms being predominant. IL-
4 stimulation increased the expression of β, γ, and δ
isoforms but not α isoform in two cell lines. In conclusion,
there is constitutive expression and activation of p38
MAPK in a large number of B-lymphoma-derived cell
lines and primary lymphoma tissues, supportive of its role
in lymphomagenesis. The differential IL-4 regulation of
p38 MAPK expression in cell lines derived from DLBCL
may relate to the cellular origin of these neoplasms.
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Introduction
The p38 mitogen activated protein kinase (MAPK) family
consists of serine–threonine protein kinases which are
activated in response to stress, cytokine, or growth factor
stimulation [1–5]. P38 MAPK plays a critical role in
various signaling pathways that regulate cell proliferation,
differentiation, apoptosis, and induction of cytokine pro-
duction [6–12]. Recent studies have identified four iso-
forms of p38 MAPK in mammals, and these have been
designated as p38α [2], p38β [13, 14], p38γ [15, 16], and
p38δ [17, 18]. Further studies have indicated that these
protein kinases represent related, but significantly distinct,
MAPK subgroups [19–24].
The role of p38 MAPK in the physiology of normal
hematopoietic cells and the pathogenesis of lymphoproli-
ferative disorders is largely unknown. The p38 MAPK
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DOI 10.1007/s12308-009-0049-5pathway is necessary for CD40-induced gene expression
and proliferation in normal B lymphocytes [25]. Our
previous studies using cDNA microarray analysis and
immunohistochemistry demonstrated that transformation
of follicular lymphoma to diffuse large B cell lymphoma
(DLBCL) is associated with increased expression of genes
within the ras-p38 MAPK pathway and upregulation of
phosphorylated p38 MAPK protein [26].
To investigate the role of p38 MAPK in lymphoma-
genesis, we analyzed the prevalence and pattern of
expression of p38 MAPK in a diverse group of human
lymphoma cell lines and tissue biopsies from B cell non-
Hodgkin lymphoma (NHL). Secondly, we examined the
effects of interleukin-4 (IL-4) on gene expression and in
vitro activity of p38 MAPK in five cell lines derived from
DLBCL. Our studies show constitutive expression of p38
MAPK and its activated form in cell lines derived from
human lymphoid tumors as well as in primary tissue
biopsy samples. Furthermore, there is differential expres-
sion and regulation of p38 MAPK isoforms by IL-4 in
lymphoma-derived cell lines. We also show that IL-4 is a
potent regulator of p38 MAPK in lymphoma-derived cell
lines which may be dependent on their putative cell of
origin.
Materials and methods
Cell studies
Cell lines derived from a variety of human B cell
lymphoma-derived cell lines, including activated B cell
(ABC) subtype (OCI-Ly-10 and Sudhl-5) and germinal
center B cell (GCB) subtypes (OCI-Ly-1, Sudhl-4, and
Sudhl-6) of DLBCL-derived cell lines (Table 1), were
obtained from either American Type Culture Collection
(Rockville, MD) and German Collection of Microorganism
and Culture (Braunschweig, Germany). OCI-Ly-1, Sudhl-4,
and Sudhl-6 carry the t(14;18) translocation but OCI-Ly-
10 and Sudhl-5 do not [27]. The cells were grown to
subconfluence before individual studies in RPM1-1640
medium (Nova-Tech, Inc.) supplemented with 10% fetal
bovine serum (FBS) and antibiotics. In IL-4 stimulation
studies, the cells were incubated in FBS-free RPM1-1640
media for 24 h at a concentration of 4×10
5 cells/ml,
followed by incubation in fresh FBS-free RPM1-1640
media supplemented with IL-4 of concentrations ranging
from 5 to 30 ng/ml for 24 h. Preliminary experiments have
confirmed that incubating cell lines with IL-4 at the
designated concentration for 24 h did not alter cell viability
in which more than 95% of the cells were viable as
determined by staining with Trypan blue. After 24-h
treatment with IL-4, the cells were collected by centrifugation
at 4,000 rpm at room temperature for 10 min, followed by
two washes with ice-cold PBS. The resultant cell pellets
were stored at −80°C for further analyses.
Preparation of cell lysate for in vitro kinase assays
and Western blotting analyses
The cell pellets were thawed on ice and resuspended in ice-
cold cell lysis buffer (20 mM Tris (pH 7.5), 150 mM NaCl,
1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM
sodium pyrophosphate, 1 mM Na3VO4,1μg/ml leupeptin,
and 1 mM PMSF) at a concentration of 2×10
7cells/ml.
After incubation on ice for 5 min, the mixture was
sonicated four times of 5 s each. The cell lysate was then
centrifuged at 14,000 rpm at 4°C for 10 min, and the
supernatant was collected. After the protein concentration
of the supernatant was measured with BCA assay (Pierce
Name Lineage Type Name Lineage Type
NCEB B cell MCL/t(11;14) OCI-Ly-2 B cell B-NHL
OCI-Ly-1 B cell B-NHL/t(14;18) OCI-Ly-8 B cell B-NHL
GM607 B cell EBV OCI-Ly-10 B cell B-NHL
KARPAS 422 B cell B-NHL/t(14;18) BC-1 B cell PEL + AIDS
Raji B cell African BL/t(8;14) BC-3 B cell non-AIDS PEL
GM697 B cell B-ALL/t(1;19) Sudhl-10 B cell B-NHL
NALM-6 B cell B-ALL REH B cell B-ALL/t(12;21)
GRANTA 519 B cell MCL/t(11;14) Sudhl-8 B cell B-NHL
Sudhl-4 B cell B-NHL/t(14;18) Sudhl-9 B cell B-NHL
Sudhl-5 B cell B-NHL Sudhl-16 B cell B-NHL/t(14;18)
Sudhl-6 B cell B-NHL/t(14;18)
Sudhl-7 B cell B-NHL
OCI-Ly-7 B cell B-NHL
Table 1 B cell lymphoma-
derived cell lines used for
Western blot analysis
B B cell, ALL acute lympho-
blastic leukemia, BL Burkitt
lymphoma, EBV Epstein Barr
virus transformed, MCL mantle
cell lymphoma, PEL pleural
effusion-based lymphoma, NHL
non-Hodgkin lymphoma
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at −80°C until future use.
Western blot analysis of p38 MAPK and phospho-p38
MAPK
Aliquots (30 μg) of the cell lysate proteins were separated
by 12% SDS-PAGE. A positive control was established by
stimulating OCI-Ly-1 cells with 25 μg/ml anisomycin
(Sigma, St. Louis, MO) for 20 min at standard culture
condition. Ten micrograms of the cell lysate protein of the
positive control was loaded to each gel. After electropho-
resis, the proteins were transferred to nitrocellulose mem-
brane at 10 V for 35 min using a Bio-Rad semi-dry transfer
cell (Bio-Rad Laboratories, Inc., Hercules, CA). The
membrane was washed for 5 min in Tris Buffer Saline
Tween (TBST) buffer followed by incubation in blocking
buffer (TBST buffer with 0.5% dry milk) for 1 h at room
temperature. The membrane was then washed three times
with TBST and subsequently treated with primary antibody
(Cell Signaling Technology, Beverly, MA) at 1:1,000
dilutions in antibody buffer (TBST with 0.5% BSA),
overnight at 4°C. The membrane was then washed three
times in TBST buffer followed by incubation in horseradish
peroxide-conjugated secondary antibody at 1:1,000 dilutions
in blocking buffer, for 1 h at room temperature. After another
three washes with TBST buffer, the blot was developed with
luminol reagent (Santa Cruz Biotechnology, Santa Cruz,
CA) for 1–3 min followed by exposure to Kodak Biomax
Light Film (Fisher Scientific, Pittsburgh, PA). Assays were
performed in triplicate for each sample and anti-β-actin
antibody was used as a loading control. The density of the
bands representing p38 MAPK and p-p38 MAPK was
corrected by that of the positive control and designated as
standardized densitometry units (SDU). In IL-4 dose-
response studies, SDU of the treated cells was corrected by
the SDU of the untreated cells and designated as relative p38
MAPK and phospho-p38 MAPK expression. Mean values of
the triplicate assays are reported in the results section.
In vitro p38 MAPK activity assay
In vitro p38 MAPK assay was performed using a
commercial kit from Cell Signaling Technology (Beverly,
MA). Briefly, 200 μg of cell lysate protein was incubated
with 20 μl of immobilized phosphorylated p38 MAPK
(p-p38 MAPK) monoclonal antibody overnight at 4°C in
cell lysis buffer to precipitate p-p38 MAPK protein. After a
wash with ice-cold cell lysis buffer and a subsequent two
washes with kinase assay buffer (25 mM Tris (pH 7.5),
5m Mβ-glycerophosphate, 2 mM DTT, 0.1 mM Na3VO4,
10 mM MgCl2, and 200 μM ATP), the precipitated p-p38
MAPK was incubated overnight at room temperature, in
50 μl of kinase buffer supplemented with 2 μg of the
substrate protein, ATF-2 fusion protein. The reaction was
terminated by adding six times the SDS sample loading
buffer to the assay mixture followed by boiling the
specimen for 4 min. Aliquot of 30 μl of the mixture was
loaded onto and separated on 12% SDS-PAGE gel and then
transferred to nitrocellulose membrane. The phosphorylated
ATF-2 protein was detected by Western blot analysis, as
described above. To standardize the loading consistency,
15-μl aliquot of the reaction mixture was loaded onto a
parallel 12% SDS-PAGE gel, and after electrophoresis and
transfer, total (phosphorylated and unphosphorylated)
ATF-2 protein was determined by Western blot analysis.
Ten micrograms of the cell lysate of the anisomycin-
stimulated OCI-Ly-1 cells was used as positive control for
each in vitro p38 MAPK assay and subjected to the same
immunoprecipitation, in vitro kinase assay, and Western
blotting analysis, serving to normalize interblot variation
(see statistical analysis). Ten microliters of cell extract from
unstimulated NIH/3 T3 cell (Cell Signaling Technology)
was used as a negative control for each assay.
Three independent experiments were performed for the in
vitro p38 MAPK activity assay. The ratio of the density of
phosphorylated-ATF-2 (p-ATF-2) to that of total ATF-2 was
designated as the in vitro p38 MAPK activity. We normalized
the in vitro p38 MAPK activity by dividing the in vitro p38
MAPK activity of individual cell lines by the in vitro p38
MAPK activity of the positive control. In IL-4 dose-response
studies,wenormalizedtheinvitrop38MAPKbydividingthe
in vitro p38 MAPK activityof the treated cells withthatof the
untreated cells and expressed as relative p38 MAPK activity.
The mean of the relative in vitro p38 MAPK activity of the
triplicate assays are reported in the Results section.
Immunohistochemistry
Immunohistochemical studies were performed on 5-μmt h i c k
formalin-fixed paraffin-embedded tissue sections. Heat-
induced epitope retrieval in citrate buffer (pH 6.0) for 15 min
was used. An avidin–biotin peroxidase complex method was
employed using an automated immunostainer (Ventana
Medical Systems, Tucson, Arizona). Anti-human p-p38
MAPK antibody (Cell Signaling Technology, Inc., Beverly,
MA) was utilized at a dilution of 1:60. Reactive lymph nodes
were used as tissue control in which germinal center B cells
show negligible expression of p-p38 MAPK while inter-
follicular T cells show predominantly nuclear expression of
p-p38 MAPK. Immunohistochemical analysis of p-p38
MAPK expression in lymphoma tissue samples was inter-
preted by two hematopathologists (M.S.L. and K.E.J.). To
increase the interobserver agreement level, immunoreactivity
was interpreted as positive if greater than 50% of the tumor
cells showed nuclear expression of p-p38MAPK (Table 2).
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MAPK
Total RNA was extracted from four DLBCL-derived cell lines
(Sudhl-4,Sudhl-6,OCI-Ly-1, and OCI-Ly-10)that were treated
with and without 5 ng/ml of IL-4 for 24 h and from
phenotypically purified germinal center B-cells [28]u s i n ga
modified TRIzol extraction protocol (Invitrogen, Carlsbad,
CA). cDNA was reverse-transcribed using the SuperScript II
kit according to manufacturer's instructions (Invitrogen,
Carlsbad, CA). Quantitative fluorescent reverse transcriptase-
polymerase chain reaction (RT-PCR) was performed using the
LightCycler™ (Roche Molecular Biochemicals, Indianapolis,
IN) and SYBR Green I™ (Molecular Probes, Eugene, OR)
[29]. From each sample, 50 ng/μl cDNA was amplified in
triplicate using primer pairs specific for each of the p38MAPK
isoforms (α, β, γ,a n dδ) and the control gene EMP 4.1L 1 .
The sequences of the primers used for quantitative RT-PCR
are listed in Table 3. Reactions consisted of 45 cycles of
denaturation at 94°C (0 s), annealing at 55°C (0 s), and
extension at 72°C (15 s). Fluorescence signals were obtained
from each sample after the extension phase of each cycle. The
crossing threshold or entry in to the logarithmic phase of PCR
for each sample was determined by calculating the second
derivative maximum using LightCycler™ software version
3.5.3.
The expression of the p38 MAPK isoforms in each cell
line relative to that of germinal center B cells was
calculated as previously described [30]. In studies where
effects of IL-4 on expression of p38 isoforms were
examined, the expression values of the treated cells were
further corrected by the values obtained in the untreated
cells and expressed as relative expression units. The
arithmetic means of the triplicate quantitative RT-PCR
assays are reported in the Results section.
Results
Expression of native and phospho-p38 MAPK in human
lymphoma cell lines and primary B cell non-Hodgkin
lymphoma tissues
We analyzed the expression of p38 MAPK and their
phosphorylation status (p-p38 MAPK) using Western blot
analysis. Both the native and p-p38 MAPK proteins were
detected in all B cell lymphoma cell lines (Fig. 1a, Table 1).
As compared with normal lymphocytes isolated from
peripheral blood, most of the cell lines derived from B cell
lymphoma showed up-regulation in expression of p38
MAPK. However, p-p38 MAPK showed variable expres-
sion among the tested cell lines (Fig. 1a). We also evaluated
the expression of p-p38 MAPK by immunohistochemistry
in a panel of 30 B cell NHL tissue biopsies representing the
most common human NHL composed of follicular lym-
phoma (n=6); chronic lymphocytic leukemia/small lym-
phocytic lymphoma (CLL/SLL; n=6); mantle cell
lymphoma (n=14); and diffuse large B-cell lymphoma
(n=14). Constitutive expression of p-p38MAPK was
detectable within the nucleus of lymphoma cells in 1/6
(17%) follicular lymphomas, 2/6 (33%) CLL/SLL, 11/14
(78%) mantle cell lymphoma (MCL), and 13/14 (93%)
DLBCLs (Fig. 1b). In contrast, reactive germinal centers
from six lymph nodes showed negligible levels of p-p38
indicating that this pathway is deregulated in a variety of B-
lineage NHLs.
Table 2 Immunohistochemical analysis of p-p38 MAPK expression
in B cell NHL tissue biopsies
Diagnosis Number
of cases
analyzed
Number
of cases
showing
<50% p-p38
Number
of cases
showing
>50% p-p38
Percentage of
cases showing
>50% p-p38
(%)
CLL/SLL 6 4 2 33
FCL 6 5 1 17
MCL 14 3 11 78
DLBCL 14 1 13 93
CLL/SLL chronic lymphocytic leukemia/small lymphocytic lympho-
ma, FCL follicular lymphoma, MCL mantle cell lymphoma, DLBCL
diffuse large B cell lymphoma
Primer Sequence GenBank accession number
MAPKp38alphaF ACTCAGATGCCGAAGATGAAC NM_001315
MAPKp38alphaR GTGCTCAGGACTCCATCTCT NM_001315
MAPKp38betaF CCCGGACATATATCCAGTCC AF001008
MAPKp38betaR TCACTGCTCAATCTCCAGG AF001008
MAPKp38gammaF GCCCATCCCTACTTCGAGTC U66243
MAPKp38gammaR CTTCACAGAGGCGTCTCCTT U66243
MAPKp38deltaF GGCAGTTTAACGTGGCCTGTTA AF092535
MAPKp38deltaR ACAGTGGATGAATGGAAGCAGC AF092535
Table 3 Primers used for
quantitative RT-PCR
198 J Hematopathol (2009) 2:195–204Expression of p38 MAPK and p-p38 MAPK
in DLBCL-derived cell lines
Using Western blot analysis, we evaluated the expression of
p38 MAPK and p-p38 MAPK in five cell lines derived
from DLBCLs, Sudhl-4, Sudhl-6, OCI-Ly1, OCI-Ly10, and
Sudhl-5. Both native p38 MAPK and p-p38 MAPK were
detected in the five DLBCL cell lines (Fig. 2a, b). Except in
Sudhl-6, the levels of both proteins in the DLBCL cell lines
are relatively uniform, varying between 1 and 2.19 SDU for
p38 MAPK and between 1 and 2.21 SDU for p-p38
MAPK, respectively (Fig. 2b). Interestingly, the levels of
both p38 MAPK and p-p38 MAPK in Sudhl-6 are
significantly higher than in the other four cell lines, with
the levels of p38 MAPK and p-p38 MAPK being 8.01 and
3.72 SDU, respectively (Fig. 2b).
In vitro p38 MAPK activity in DLBCL-derived cell lines
To determine whether the expression of activated
p38MAPK correlated with in vitro kinase activity, we used
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p-p38 MAPK
a
b
β-actin
p38 MAPK
p-p38 MAPK
β-actin
G
M
6
9
7
N
a
l
m
-
6
G
r
a
n
t
a
5
1
9
S
U
D
H
L
-
4
N
C
E
B
O
C
I
-
L
Y
-
1
G
M
6
0
7
K
a
r
p
a
s
4
2
2
R
a
j
i
S
U
D
H
L
-
5
S
U
D
H
L
-
7
S
U
D
H
L
-
6
O
C
I
-
L
Y
-
7
P
B
L
P
B
L
 
+
 
P
H
A
O
C
I
-
L
Y
-
8
O
C
I
-
L
Y
-
2
O
C
I
-
L
Y
-
1
0
S
U
D
H
L
-
1
0
B
C
-
1
R
E
H
B
C
-
3
S
U
D
H
L
-
8
S
U
D
H
L
-
9
S
U
D
H
L
-
1
6
Reactive GC FCL low p-p38
CLL/SLL high p-p38 CLL/SLL low p-p38
MCL high p-p38 MCL low p-p38
DLBCL high p-p38 DLBCL low p-p38
Fig. 1 a Western blot analyses of expression of native (p38 MAPK)
and phosphorylated p38 MAPK (p-p38 MAPK) in human-derived B
cell lymphoma cell lines. For comparison, p38 MAPK and p-p38
MAPK also done in peripheral blood lymphocytes (PBL) and
phytohemagglutinin-stimulated PBL (PBL+PHA). The experiments
were performed in triplicate, and results shown are from the same
experiment. b Immunohistochemical analysis of p-p38 MAPK in
reactive lymphoid tissue and B cell NHL tissue samples. Germinal
center B cells within reactive lymphoid tissue show negligible
expression of p-p38 MAPK. Representative cases of FCL and CLL/
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Fig. 2 a Representative Western blot analyses of p38 MAPK and
p-p38 MAPK expression in five cell lines derived from DLBCLs,
OCI-Ly-10, Sudhl-5, OCI-Ly-1, Sudhl-4, and Sudhl-6. b Relative
expression of p38 and p-p38 MAPK in the five lymphoma-derived
cell lines expressed in standardized densitometry units (SDU). Each
data point represents the mean of triplicate assays
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MAPK. As shown in Fig. 3, the cell lysates from all five
DLBCL-derived cell lines showed in vitro p38 MAPK
activity as evidenced by the expression of phosphorylated
ATF-2 which is a substrate of p38 MAPK. Sudhl-5 and
Sudhl-6 cells display the highest level of p38 MAPK
activity while Sudhl-4 cells express the lowest p38 MAPK
activity. When the kinase activity of the cell lines is
corrected to the level in Sudhl-4, the relatively p38 MAPK
activity of Sudhl-5, Sudhl-6, Ly-1, and Ly-10 are 2.63,
2.41, 1.86, and 1.43, respectively (Fig. 3b).
Effects of IL-4 on expression of p38 MAPK and p-p38
MAPK of DLBCL-derived cell lines
To determine whether IL-4, a key cytokine that regulates
the differentiation and proliferation of normal B-
lymphocytes, regulates the expression of p38 MAPK and
p-p38 MAPK in lymphoma-derived cell lines, we assessed
the expression of these proteins after exposure to recombi-
nant IL-4. Stimulation of the five cell lines to varying
concentrations of IL-4 for 24 h showed no effect on the
expression of native p38 MAPK in all cell lines (Figs. 4
and 5a). This was not the case for p-p38 MAPK. A dose-
dependent increase in p-p38 MAPK was seen in OCI-Ly-10
and Sudhl-5 cells; both are ABC-like DLBCL-derived cell
lines, in contrast to GCB-like DLBCL-derived cell lines
including OCI-Ly-1, Sudhl-4, and Sudhl-6 cells, where
there was no significant effect on the levels of p-p38
MAPK (Figs. 4 and 5b). In OCI-Ly-10, the peak effective
level of IL-4 was 5 ng/ml which resulted in a 2.3-fold
increase in p-p38 MAPK, while in Sudhl-5, the peak
effective concentration of IL-4 was 10 ng/ml which resulted
in a 2.6-fold increase in p-p38 MAPK. Higher concen-
trations of IL-4 demonstrated no significant increase in
p-p38 MAPK expression in either OCI-Ly-10 or Sudhl-5
cell lines. These data indicate that, in cell lines that show
relatively high constitutive expression of p38 MAPK and
p-p38 MAPK (OCI-Ly-1, Sudhl-4, and Sudhl-6), IL-4
stimulation did not induce a significant increase in
expression of the proteins. In cell lines that exhibited
relatively lower levels of p38 MAPK and p-p38 MAPK
(OCI-Ly-10 and Sudhl-5), however, IL-4 induced a signif-
icant increase in the expression of p-p38 MAPK but not
native p38 MAPK.
Effect of IL-4 on in vitro p38MAPK activity
in DLBCL-derived cell lines
We investigated the effect of IL-4 on the in vitro activity of
p38 MAPK. IL-4 induced a dose-dependent increase in p38
MAPK in vitro activity in all the five cell lines (Fig. 6a, b).
Except in Sudhl-5, the peak effective level of IL-4 is
5 ng/ml with the increase in p38 MAPK in vitro activity
ranging from 1.57- to 2.33-fold of the basal levels. In these
cell lines, further increase in IL-4 concentration was
associated with a gradual decrease in p38 MAPK in vitro
activity to the levels either compatible to the basal levels, as
in Sudhl-6, OCI-Ly-1, and OCI-Ly-10, or below the basal
level, as in Sudhl-4. In Sudhl-5, the peak effective level of
IL-4 is 10 ng/ml which induced 3.21 times increase in p38
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200 J Hematopathol (2009) 2:195–204MAPK in vitro activity. The in vitro p38 MAPK activity in
Sudhl-5 decreased with further increase in IL-4 concentra-
tion but did not return to basal level. Furthermore, the data
indicate that there is a positive correlation between the
levels of p-p38 MAPK and its in vitro kinase activity.
Discussion
Our previous studies showed increased expression of p38
MAPK transcript and protein in a subset of DLBCL arising
from follicular lymphomas [26]. In addition, lymphoma
cells in DLBCL displayed strong nuclear reactivity for
p-p38 MAPK, while follicular lymphoma cells were often
negative. Similar observations were obtained recently by
Ogasawara et al. [31] who found that freshly prepared cells
from B cell lymphomas showed constitutive in vitro
activity of p38 MAPK and ERK but not Ras, Akt kinase,
and JNK kinase. These observations suggest that constitu-
tive activation of the p38 MAPK pathway may be
implicated in lymphomagenesis.
In the current study, we have examined the expression of
p38 and p-p38 MAPK proteins in cell lines derived from a
variety of B cell-derived NHL. As shown in Fig. 1, both
proteins were detected in all human B cell lymphoma cell
lines. As compared with normal lymphocytes isolated from
peripheral blood, most of the cell lines derived from B cell
neoplasms show up-regulated expression of p38 MAPK.
The expression of p-p38 MAPK, however, was lower and
more variable. These data suggest that the p38 MAPK is
expressed and activated in neoplastic cells derived from B
cell neoplasms. Immunohistochemistry demonstrated that,
in reactive lymph nodes and tonsils, there were negligible
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represents the mean of three replicate assays and is corrected by the
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J Hematopathol (2009) 2:195–204 201levels of p-p38 MAPK in germinal center B cells, while the
mantle B cells showed weak cytoplasmic expression.
Analysis of primary tissues of B cell NHLs also demon-
strated constitutive expression of activated and nuclear
p-p38MAPK in a subset of lymphomas while germinal
center B cells showed negligible levels. Interestingly, the
low-grade B cell lymphomas (CLL/SLL and FCL) demon-
strated lower percentage of tumor cells exhibiting p-p38
MAPK expression, while the aggressive lymphomas (MCL
and DLBCL) exhibited higher percentage of cases and
tumor cells exhibiting p-p38 MAPK expression. The p-p38
expression does not merely indicate proliferation status
since p-p38 MAPK is not expressed in reactive germinal
center B cells (Fig. 1b). The high percentage of MCL and
DLBCL cases with p-p38 MAPK expression (78% and
93%, respectively) may be reflective of the presence of
cytokines or growth factors that activate the p38 MAPK
pathway in these tumors.
We determined whether expression of p38 MAPK and
p-p38 MAPK is associated with its functional kinase
activity. As demonstrated in Fig. 3a, b, cell lysates from
five DLBCL-derived cell lines showed readily detectable in
vitro p38 MAPK activity using ATF2, a natural substrate
for the kinase activity of p38 MAPK. There was a positive
correlation between the levels of p-p38 MAPK as deter-
mined by Western blot analysis and the in vitro p38 MAPK
activity.
Although the role of p38 MAPK is thought to be central
to many key cellular processes such as the production of
IL-6, cell proliferation, and apoptosis in many cell systems,
the regulation of p38 MAPK expression in normal and
neoplastic lymphocytes has not received much attention in
the literature. CD40 ligand provides a co-stimulatory signal
that induces p38 MAPK activation and results in the
differentiation and proliferation of B cells [25]. Type I
interferons can activate p38 MAPK in T-lymphoblastic
leukemia-derived cells and Burkitt lymphoma-derived cells
[32, 33], and toll-like receptor 2 can induce p38 MAPK
expression in HEK293 cells [34]. In addition, recent studies
found that IL-4 induces the activation of p38 MAPK in
endometriotic stromal cells [35].
However, little is known regarding the extracellular
regulators of p38 MAPK expression in neoplastic B cells.
Thus, we investigated the potential role of IL-4 in the
regulation of the expression and activity of p38 MAPK. IL-
4 is a well characterized cytokine that is produced by
normal CD4+ T cells and is important in regulation of
normal B cell differentiation and proliferation [36]. High
levels of IL-4 have been observed in culture supernatants
from B and T cells from chronic lymphocytic leukemia
(CLL) patients [37, 38]. IL-4 may promote survival and
viability of CLL cells by preventing apoptosis [37]. Our
current study data shows that IL-4 stimulation induced the
expression of p-p38 MAPK as well as the in vitro p38
MAPK activity in cell lines derived from B cell lymphomas
while previous studies showed that IL-4 failed to stimulate
the enzymatic activity of p38 MAPK or MAPKAP kinase-
2, a downstream kinase in the p38 MAPK pathway. These
studies were, however, limited to the analysis of primary
mast cell cultures and cultured factor-dependent hemato-
poietic cell lines MC/9 and DS-MACII [4]. The finding that
the level of p-p38 MAPK in OCI-LY-10 cell line reached a
plateau at 5 ng/ml Il-4 with minimal increase at 20 ng/ml
Il-4 may be due to the susceptibility of OCI-LY-10 to
low-dose Il-4 sensitization or prolonged receptor–ligand
interactions. These observations further suggest that IL-4-
mediated activation of p38 MAPK may be highly cell-type
specific. IL-4 has been shown to activate p38 MAPK-
dependent pathways in a number of other cell types
including keratinocytes [39].
We also found that expression of p-p38 MAPK and in
vitro kinase activity among cell lines derived from
DLBCLs was cell-type dependent. Whereas expression
and activity of p38MAPK in Sudhl-4, Sudhl-6, and OCI-
Ly-1 cells were higher than in Sudhl-5 and OCI-Ly-10
cells, the latter cell lines responded more potently to
induction by IL-4. Interestingly, these two cell lines do
not harbor the t(14;18) chromosomal aberration and have
been regarded as equivalents of the activated B cell
lymphoma subtype in cDNA microarray studies [40].
Tissue distribution of different isoforms of p38 MAPK
mRNA has been studied [2, 13–18, 41–43]; however, there
is no information on expression of these isoforms in B cells
or B cell lymphoma cells. Our data show that both reactive
germinal center B cells and cells derived from DLBCL
express all four isoforms of p38 MAPK at the RNA level
(supplementary Fig. 1). The most predominant isoform of
p38 MAPK expressed in cell lines derived from DLBCL
was p38γ, followed by p38β, while the expression of p38α
and p38δ was minimal. These data further highlight the
complexity of regulation of p38 MAPK isoform expression
by which IL-4 may play a role in regulating p38 MAPK
pathway (supplementary Fig. 2).
In conclusion, our data indicate that constitutive
activation of the p38 MAPK may represent an important
pathogenetic mechanism in B cell lymphomas. This
study documents the differential expression of isoforms
of the p38 MAPK gene in DLBCL-derived cell lines,
implicating its possible deregulation in the pathogenesis
of these neoplasms. We present, evidence that IL-4 may
be an important regulator of the p38 MAPK signaling
pathway with stimulatory effects on gene expression,
protein levels, and in vitro kinase activity. The data
suggest a possible role for IL-4-mediated activation of
p38 MAPK signaling pathway in the pathogenesis of B
cell lymphomas.
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